US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.71

+0.28070.99%

Post-market: 28.710.00000.00%16:10 EDT

Volume:425

Turnover:12.14K

Market Cap:2.58M

PE:- -

High:28.71

Open:28.54

Low:28.38

Close:28.43

52wk High:28.93

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.36

T/O Rate:0.47%

Dividend:0.92

Dividend Rate:3.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Hemab Therapeutics doses first patient in HMB-003 trial

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

Fennec presents results from STS-J01 clinical trial evaluating Pedmark

Rakovina Therapeutics Adds Yale DNA Repair Expert to Scientific Advisory Board

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream

MT Newswires Live

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Optimi Health to Launch Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers

Hansoh Pharma Wins NMPA Nod for Clinical Trials of Innovative Cancer Drug HS-20197

TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU

Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA

Barclays downgrades Scholar Rock on valuation after FDA approval

AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

Immunocore achieves target patient enrollment in TEBE-AM clinical trial

Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803

Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NVIB/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.7085,"timestamp":1790884800000,"preClose":28.4278,"halted":0,"volume":425,"hourTrading":{"tag":"盘后","latestPrice":28.7085,"preClose":28.7085,"latestTime":"16:10 EDT","volume":6,"amount":172.251,"timestamp":1790885404179,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0098741372881475,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Post-Mkt","change":0.2807,"latestTime":"10-01 16:40:50 EDT","open":28.54,"high":28.7085,"low":28.38,"amount":12136,"amplitude":0.011556,"askPrice":43.09,"askSize":200,"bidPrice":14.37,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790899200000},"marketStatusCode":4,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.4278,"nav":28.36,"aum":2552427.21,"dividendRate":0.031984,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.7085,"preClose":28.7085,"latestTime":"16:10 EDT","volume":6,"amount":172.251,"timestamp":1790885404179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.360231},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.360231,"shares":90001,"dividePrice":0.9182,"high":28.7085,"amplitude":0.011556,"preClose":28.4278,"low":28.38,"week52Low":24.54,"pbRate":"--","week52High":28.93,"institutionHeld":0,"latestPrice":28.7085,"eps":0,"divideRate":0.031984,"volume":425,"delay":0,"ttmEps":0,"open":28.54,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":27.9349,"twentyDayClose":27.8834},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668196234","title":"Hemab Therapeutics doses first patient in HMB-003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668196234?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:05","pubTimestamp":1789646751,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","LENZ","BK4007","HYLG","COAG","BK4539","NVIB","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996120","title":"Nuvation Bio announces FDA approval of sNDA for Ibtrozi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996120","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996120?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644932,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the tre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","RSPH","IDNA","LABU","MRNX","GNMX","NVIB","BK4007","TECB","MEDI","FRTY","SYNB","XLVX","PSCH","BK4585","NUVB","GDOC","MRNY","BMED","BBP","LFSC","IBB","TBXU","IYH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668196173","title":"Fennec presents results from STS-J01 clinical trial evaluating Pedmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668196173?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644911,"startTime":"0","endTime":"0","summary":"Fennec (FENC) announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating Pedmark...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fennec-presents-results-from-sts-j01-clinical-trial-evaluating-pedmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fennec-presents-results-from-sts-j01-clinical-trial-evaluating-pedmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","HYLG","GDOC","IDNA","FENC","NVIB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963402","title":"Rakovina Therapeutics Adds Yale DNA Repair Expert to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963402?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:32","pubTimestamp":1789637575,"startTime":"0","endTime":"0","summary":"Rakovina Therapeutics Inc ( ($TSE:RKV) ) just unveiled an announcement. Rakovina Therapeutics has appointed Yale physician-scientist and biotech en...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-adds-yale-dna-repair-expert-to-scientific-advisory-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-adds-yale-dna-repair-expert-to-scientific-advisory-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","LENZ","NVIB","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963474","title":"Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963474?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:30","pubTimestamp":1789637420,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustai...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","RSPH","GNMX","LFSC","XLVX","PINK","NVIB","SYNB","MRNY","IBB","IYH","PSCH","BK4588","MEDI","GDOC","BK4007","TECB","IEIH","FRTY","BMED","BK4585","TBXU","BBP","BAYRY","LABU","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668959271","title":"Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959271","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668959271?lang=en_us&edition=fundamental","pubTime":"2026-09-17 14:17","pubTimestamp":1789625847,"startTime":"0","endTime":"0","summary":"Bailing Yuxiu  Pharmaceutical, a wholly-owned subsidiary of Guizhou Bailing Group Pharmaceutical , has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.The clinical trial application was approved subject to further refinement of the trial protocol.In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.The company said the cream could potentially complement its Tangning Tongluo tablets to form an \"oral plus topical\" treatment system.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002424","HYLG","GDOC","BK0183","BK0077","BK0239","IDNA","NVIB","MEDX","BK0028","BK0146","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","FBT","IDNA","BK4588","GDOC","TBXU","LGVN","CNCR","BK4585","GNOM","LFSC","MEDX","NVIB","SYNB","HYLG","BK4139","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667840559","title":"Optimi Health to Launch Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers","url":"https://stock-news.laohu8.com/highlight/detail?id=2667840559","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667840559?lang=en_us&edition=fundamental","pubTime":"2026-09-16 23:38","pubTimestamp":1789573088,"startTime":"0","endTime":"0","summary":"Optimi Health ( ($TSE:OPTI) ) has shared an update. Optimi Health plans to launch a Health Canada-authorized Phase 3 clinical trial in 2027 to eval...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/optimi-health-to-launch-phase-3-mdma-trial-for-ptsd-in-veterans-and-frontline-workers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/optimi-health-to-launch-phase-3-mdma-trial-for-ptsd-in-veterans-and-frontline-workers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","NVIB","HYLG","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601377","title":"Hansoh Pharma Wins NMPA Nod for Clinical Trials of Innovative Cancer Drug HS-20197","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601377","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601377?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:12","pubTimestamp":1789549943,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited ( ($HK:3692) ) has issued an announcement. Hansoh Pharmaceutical Group has received clinical trial appr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hansoh-pharma-wins-nmpa-nod-for-clinical-trials-of-innovative-cancer-drug-hs-20197?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hansoh-pharma-wins-nmpa-nod-for-clinical-trials-of-innovative-cancer-drug-hs-20197?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","HYLG","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667089246","title":"TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2667089246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667089246?lang=en_us&edition=fundamental","pubTime":"2026-09-16 14:37","pubTimestamp":1789540665,"startTime":"0","endTime":"0","summary":"TME Pharma N.V. ( ($FR:ALTME) ) has provided an announcement. TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BYQNZ168.SGD","LU0359202008.SGD","LU1023057109.AUD","01698","XBIX","LU0828238088.HKD","TME","BK4571","LU0269904917.USD","SG9999011746.SGD","NVIB","LU0456842615.SGD","BK4565","LU0509642566.USD","IE00B12V2V27.USD","BK4531","BBC","DBB","LU0359201612.USD","BK4535","BK4552","BK4526","BK4548","LU2039709279.SGD","BK4563","BK4509","BK4108","IE00BYTNYN87.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667671746","title":"ASX biotech expands diagnostics portfolio after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671746","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667671746?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:00","pubTimestamp":1789488000,"startTime":"0","endTime":"0","summary":"Telix Pharmaceutical’s (ASX.TLX) Pixclara becomes the first positron emission tomography, or PET, imaging agent for glioma brain cancer to receive approval from the US Food and Drug Administration.Why","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["RSPH","MEDI","BBP","SYNB","TBXU","IYH","BMED","XBIX","IDNA","GNMX","GDOC","FRTY","MRNY","PSCH","LABU","TECB","XLVX","BK4585","NVIB","MRNX","IBB","LFSC","BK4588","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644329","title":"Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644329","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644329?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:35","pubTimestamp":1789472125,"startTime":"0","endTime":"0","summary":"Arrowhead (ARWR) Pharmaceuticals announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigation...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-interim-topline-data-from-phase-1-2a-trial-of-aro-dimer-pa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-interim-topline-data-from-phase-1-2a-trial-of-aro-dimer-pa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","MEDX","HYLG","BK4588","IDNA","BK4585","ARWR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IDNA","TBXU","BMED","LABU","PSCH","RSPH","GDOC","TSPA","PINK","SYNB","IBB","MEDI","TACU","GNMX","LFSC","TECB","XLVX","MRNY","IYH","IEIH","NVIB","CDIG","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691804","title":"AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691804?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:16","pubTimestamp":1789427795,"startTime":"0","endTime":"0","summary":"The latest update is out from AdAlta Ltd. ( ($AU:1AD) ). AdAlta Limited, an Australian clinical-stage biotech specialising in cellular immunotherap...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BBC","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLVX","GDOC","GNMX","FRTY","BMED","BK4007","IEIH","MRNY","MRNX","BBP","RSPH","IYH","BK4588","IBB","LFSC","PINK","SYNB","IDNA","NVIB","TBXU","TECB","PSCH","MEDI","BK4585","BFRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","TBXU","IEIH","MRNY","IDNA","GDOC","BK4585","XLVX","BK4588","SYNB","NVIB","RSPH","BBP","LFSC","LABU","MRNX","BMED","TECB","FRTY","MEDI","IBB","PINK","PSCH","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","TECB","BMED","LABU","IEIH","THNR","SYNB","GNMX","XLVX","IYH","NVIB","PINK","MEDI","BBP","MRNY","BK4585","IBRN","BK4139","IDNA","LFSC","MRNX","SRRK","RSPH","BK4588","GDOC","PSCH","FRTY","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668170","title":"Immunocore achieves target patient enrollment in TEBE-AM clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668170?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:20","pubTimestamp":1789384814,"startTime":"0","endTime":"0","summary":"Immunocore (IMCR) announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","IMCR","MEDX","NVIB","HYLG","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576635","title":"Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576635","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667576635?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:19","pubTimestamp":1789341541,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing pre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000WXP2NQ0.USD","IE000HOSIQF4.USD","IE00BMG7P587.USD","IE00BMG7P926.USD","IE00BMG7P702.HKD","BK4144","TRP","MLPX","IE00BMG7P694.USD","BK4566","XBIX","IE00BD4GTV84.USD","IE00BD4GTT62.SGD","IE00BMG7P819.SGD","TPYP","IE00BD4GTW91.USD","BBC","EINC","NVIB","IE000SL1IH01.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635880","title":"Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635880?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:56","pubTimestamp":1789340203,"startTime":"0","endTime":"0","summary":"Noxopharm Ltd. ( ($AU:NOX) ) has provided an update. Australian biotech Noxopharm is advancing its lead topical therapy SOF-SKN, developed from its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/noxopharm-advances-sof-skn-into-cle-extension-study-to-target-autoimmune-skin-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/noxopharm-advances-sof-skn-into-cle-extension-study-to-target-autoimmune-skin-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","SOF"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}